MedTrace Logo

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

NCT06455072 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-06-12

No results posted yet for this study

Summary

In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy. However, immune checkpoint inhibitor's combination therapy has become a promising strategy for advanced cervical cancer. Epidermal Growth Factor Receptor (EGFR) is overexpressed in cervical cancer cells. Stereotactic radiotherapy (SBRT) can enhance the efficacy of immunotherapy.

Conditions

Interventions

DRUG

Nituzumab

EGFR monoclonal antibody

DRUG

Serplulimab

PD-1 (programmed death receptor 1) monoclonal antibody

Sponsors & Collaborators

  • Zhangzhou Municipal Hospital of Fujian Province

    collaborator OTHER

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Qin Xu · Fujian Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06455072 on ClinicalTrials.gov